Medtronic, the world’s largest medical technology, services, and solutions company, and Renescor, Limited Liability Partnership, have signed a partnership deal to bring high quality cardiac care and healthcare managed services to the purpose-built Gbagada Cardiac and Renal Centre (CRC) in Lagos.
Renescor was recently awarded a five-year concession agreement with the Lagos State Government to activate and bring high quality services to the purpose-built Gbagada Cardiac and Renal Centre (CRC). Renescor is partnering with Medtronic to help manage CRC’s Cath-Lab, Operating Room (OR) and ICU.
Chairman of Renescor, Dr Ladi Awosika, explained: “Nigeria is in desperate need for efficient Cath-Labs and operating rooms (OR) to treat more patients locally. Lagos currently has only two operational Cath-Labs to serve a population of 16 million and is in critical need of more.”
Dr. Ladi added “We decided on Medtronic because it is the largest medical technology manufacturer globally with over 65 years of experience and positive track record of delivering value to their customers and partners. Our collaboration will ensure the hospital is run to the highest global standards of care quality, efficiency, patient safety, and optimised capacity to help more patients be treated.”
The agreement, which runs for a term of four years, will see Medtronic Integrated Health Solutions Department partnering with Renescor to help finance, manage, and optimise services in Cath-Labs, OR and ICU. The partnership consists of end-to-end management of these units, which includes operational support, staffing and material management, deployment of the latest Cardiovascular Information System, operational excellence Lean/Six sigma consulting services, continuous performance assessment and benchmarking services, advising on and implementation of growth programs, as well as training and education services for cardiovascular therapies. The aim is to transform CRC into a leading regional centre that achieves global standards of care in line with international leading institutions.
Khodor Mekkaoui, Head of Medtronic Integrated Health Solutions for Middle East, Africa, Central Asia and Turkey commented: “Our involvement at CRC is a distinctive example of Medtronic’s Integrated Health Solution offerings. We are moving beyond the supply of devices, to deliver healthcare services that would ensure more access to
patients in areas where it is currently not readily available. The Integrated Health Solution model helps optimise healthcare delivery and drives greater economic value.” This is the first undertaking of its kind by Medtronic IHS Department
in Africa, and underscores its vision to address universal healthcare needs.
Mekkaoui added: “This important contract presents a unique opportunity for Medtronic to showcase its skills and expand its footprint in Africa, where there is also a great need for investment in healthcare sector, in countries facing a lack of funding and shortage of resources.”
Dr Awosika agreed: “Many issues faced in Nigeria today are similar to those in other African nations. We believe that the Medtronic integrated health solutions can be adapted and customised to other African countries.” He added: “Medtronic’s role and dedication as a partner shows how they are truly dedicated to improving care in African nations, as can
also be seen through one aspect of their mission, which is to help in the globalisation of care by addressing inequities in healthcare access and affordability around the world.”
Renescor Limited Liability Partnership is a special purpose vehicle registered for the purpose of providing first class End Stage Renal Disease Services and Cardiology Healthcare Services to Lagos State residents and the broader Nigerian population.
Medtronic plc headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in more than 160 countries.